Human tumor xenograft models, using a broad variety of human tumor cell lines, are in routine use at Heidelberg Pharma. The efficacy of your compound can be determined in terms of tumor growth control and tumor regression on tumors differing in growth rate, response to clinical standards or expression of selected target protein. The human tumor xenograft program has been extended by several syngenic tumor models in mice.

Please find more information below: